A PHASE 1, OPEN-LABEL, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF ESOMEPRAZOLE ON THE PHARMACOKINETICS OF SINGLE DOSE VEPDEGESTRANT (ARV-471, PF-07850327) UNDER THE FED CONDITION IN HEALTHY ADULT MALES AND HEALTHY ADULT FEMALES OF NONCHILDBEARING POTENTIAL
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Esomeprazole (Primary) ; Vepdegestrant (Primary)
- Indications HER2 negative breast cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 31 May 2024 Status changed from recruiting to completed.
- 20 Mar 2024 Status changed from not yet recruiting to recruiting.
- 26 Feb 2024 New trial record